## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 3.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($157.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Cancer trial results and a major conference: inside Jazz Pharmaâ€™s update**
- Source: Stock Titan | 20251217T210904 | Somewhat-Bullish | Relevance: 100%
- Jazz Pharmaceuticals (Nasdaq: JAZZ) will host investor webcasts in January 2026 to discuss clinical and corporate updates. Key events include a webcast on January 9, 2026, to review Phase 3 zanidatamab HERIZON-GEA-01 trial results following an ASCO GI presentation, and a corporate presentation by CEO Renee Gala at the J.P. Morgan Healthcare Conference on January 13, 2026. Audio webcasts and replays will be available on the company's investor relations website.

**2. Jazz Pharmaceuticals to Participate in Upcoming Investor Events**
- Source: PR Newswire | 20251217T161500 | Somewhat-Bullish | Relevance: 100%
- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced upcoming investor events, including an investor webcast on January 9, 2026, to review results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The company will also participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where Renee Gala, president and chief executive officer, will provide a business update. Audio webcasts of these presentations will be available on the company's investor relations website for 30 days.

**3. Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Texas Permanent School Fund Corp**
- Source: MarketBeat | 20251217T080904 | Neutral | Relevance: 100%
- The Texas Permanent School Fund Corp reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 23.2% in Q2, selling 15,567 shares and retaining 51,673 shares valued at approximately $5.48 million. Despite insider selling, particularly by directors, analysts largely maintain a "Moderate Buy" consensus with an average price target of $200.47, signaling positive sentiment for the stock.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.3% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Valuation stretched: PEG 3.9x requires aggressive growth execution.
4. Elevated short interest (9.5%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.94 signals overvaluation risk, limited margin of safety. Forward P/E 7.4x attractive for 180% earnings growth. Analyst sentiment positive (2 raises, avg +32%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.1B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.94 |
| Forward P/E | 7.4 |
| Current P/E | 20.6 |
| YoY Growth | 180.1% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.4% to 0.1% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-1.4%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.32x) but short-term weakness (below SMA20). MACD histogram bearish (-1.51), momentum weakening. RSI neutral at 55. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.09% (CS: 56) | Neutral |
| RSI_14 | 55.3 | Neutral |
| MACD Histogram | -1.51 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.091x | Above |
| vs SMA200 | 1.318x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $166.99
- **Stop Loss:** $157.09 (5.9% risk)
- **Target:** $176.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $20,205.79
- **Portfolio %:** 20.21%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*